# P21 (P021)

> A CNTF-derived peptidergic compound with an adamantane group, studied as a neurogenic, BDNF-enhancing agent in Alzheimer’s models.

- Also known as: P021, P-21, CNTF-derived peptide
- Class: Cognitive
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/p21

## Overview

P21 (also written P021) is a small peptidergic compound derived from a biologically active region of ciliary neurotrophic factor (CNTF), modified with an adamantane moiety to improve stability and brain penetration. It is studied for enhancing neurogenesis and BDNF signaling and for reducing tau pathology in preclinical Alzheimer’s-disease and neurodegeneration models. It is a research compound with no clinical data and no approval.

P021 came from efforts to capture the neurotrophic activity of ciliary neurotrophic factor in a small, stable molecule. By taking an active CNTF-derived peptide and attaching an adamantane group, researchers aimed for a compound that resists breakdown and reaches the brain while promoting new neuron formation and BDNF expression.

In transgenic and aging rodent models it has been reported to increase neurogenesis, raise BDNF, and lower tau pathology and cognitive deficits. This is preclinical neuroscience research; there is no clinical trial, no human data, and no approval. This page is a research and educational reference.

## Mechanism

Derived from a CNTF peptide region; reported to antagonize the neurogenesis-inhibitor pathway and increase BDNF and neurotrophic signaling, with downstream reductions in tau hyperphosphorylation in animal models. The adamantane modification supports metabolic stability and CNS exposure.

## Research areas

Studied in: Alzheimer’s disease models, Neurogenesis, BDNF signaling, Tau pathology.

## Key research

- CNTF-derived — built from an active region of ciliary neurotrophic factor, with an adamantane modification for stability and brain penetration.
- Neurogenic and BDNF-enhancing — reported to promote neurogenesis and increase BDNF in animal models.
- Tau reduction — associated with reduced tau hyperphosphorylation in Alzheimer’s-model rodents.
- Preclinical — no human data; not FDA-approved.

## Storage, handling & synthesis

**Storage.** Store lyophilized, frozen, and protected from light; refrigerate reconstituted material for short-term use. General peptide-storage guidance applies to the peptide portion.

**Handling.** Reconstitute gently. Confirm the adamantane conjugation by analysis — characterizing only the peptide portion does not establish that the active adamantane-bearing compound is present.

**Synthesis.** A small peptidergic compound derived from ciliary neurotrophic factor and modified with an adamantane group. Synthesis couples a short peptide to the adamantane moiety, and the identity-critical step is confirming that conjugation — a certificate that characterizes only the peptide portion does not establish that the adamantane-bearing active compound was actually made.

## FAQs

### What is P21 / P021?

A CNTF-derived peptidergic compound with an adamantane group, studied for enhancing neurogenesis and BDNF signaling and reducing tau pathology in preclinical Alzheimer’s models.

### What is it studied for?

Neurogenesis, BDNF/neurotrophic signaling, and reduction of tau pathology and cognitive deficits in rodent models of neurodegeneration.

### Is there human evidence?

No — the published work is in animal models. There is no clinical trial or human safety data.

### Is it approved?

No. This page is a research and educational reference, not medical advice.

## Latest research

Recent trials and publications mentioning P021, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Transfusion Exchanges and Cognition in Sickle Cell Disease](https://clinicaltrials.gov/study/NCT07168447) — NOT_YET_RECRUITING · NCT07168447
- [Telepsychiatry in Children: Diagnostic Evaluation of Autism Spectrum Disorder](https://clinicaltrials.gov/study/NCT06622395) — UNKNOWN · NA · NCT06622395
- [Pharmacist and Data Driven Quality Improvement in Primary Care](https://clinicaltrials.gov/study/NCT03747107) — COMPLETED · NCT03747107
- [Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children](https://clinicaltrials.gov/study/NCT03649919) — WITHDRAWN · NCT03649919
- [A Care Model for Elderly Hip-fractured Persons With Cognitive Impairment and Their Family Caregivers](https://clinicaltrials.gov/study/NCT03894709) — COMPLETED · NA · NCT03894709

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/p21
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.